Core Insights - Cathie Wood's ARK Invest has increased its stake in Tempus AI, acquiring 210,000 shares, indicating confidence in the company's potential in the AI healthcare sector [1] - Tempus AI now represents 5.17% of the ARK Innovation ETF and 8.3% of the ARK Genomic Revolution ETF, highlighting its significance in ARK's investment strategy [1] Company Overview - Tempus AI is valued at $9.24 billion and operates as a mid-cap healthcare tech company that utilizes AI to analyze extensive medical data, including DNA, lab results, and clinical outcomes, to aid personalized treatment decisions [4] Financial Performance - For Q4, Tempus reported revenue of $367 million, marking an 83% year-over-year increase, with diagnostics revenue reaching approximately $266 million, up 121% year-over-year [5] - Full-year revenue totaled $1.27 billion, also an 83% year-over-year increase, with diagnostics revenue of about $955 million, reflecting a 111% year-over-year growth [6] - The company experienced organic growth of roughly 30% in its full-year results, with significant contributions from oncology and hereditary testing volumes [6] Future Outlook - CEO Eric Lefkofsky anticipates 2025 to be a remarkable year, with accelerating growth in genomics volumes and enhanced financial leverage from Tempus's platform model [7] - The company is set to report its fourth quarter and full-year earnings on February 24, which may provide further insights into its growth trajectory [7]